Format
Sort by

Send to:

Choose Destination

Search results

Items: 5

1.

Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry.

Cantú-Brito C, Chiquete E, Ruiz-Sandoval JL, Gaxiola E, Albuquerque DC, Corbalán R, Ramos A, Bhatt DL, Steg PG; REACH Latin America Collaborative Group.

Clin Cardiol. 2012 Aug;35(8):451-7. doi: 10.1002/clc.22005. Epub 2012 May 31.

2.

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE; Cassiopea Investigators.

Lancet. 2012 Jan 14;379(9811):123-9. doi: 10.1016/S0140-6736(11)61505-5. Epub 2011 Nov 28.

PMID:
22130488
3.

Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry.

Gaxiola E, Eng-Ceceña L, Ortiz-Galván F, Llamas-López L, Rangel-Guerra R, Alcocer-Gamba MA, Bhatt DL, Gabriel Steg P; Reduction of Atherothrombosis for Continued Health Registry Investigators.

Clin Cardiol. 2010 Jul;33(7):445-51. doi: 10.1002/clc.20800.

4.

Endothelial function impairment in chronic venous insufficiency: effect of some cardiovascular protectant agents.

Carrasco OF, Ranero A, Hong E, Vidrio H.

Angiology. 2009 Dec-2010 Jan;60(6):763-71. doi: 10.1177/0003319709332108. Epub 2009 Feb 23.

PMID:
19240105
5.

Spontaneous basilica vein rupture.

Ranero A, Fregoso M.

Am J Emerg Med. 2004 Sep;22(5):431-2. Review. No abstract available.

PMID:
15490390
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk